Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MC5R | P33032 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66167 | 0.92 | CACNA1B (0.47) | NPC1MEN1KMT2AALDH1A1KCNH2 | |
| SCHEMBL66703 | 0.91 | NPC1 (0.45) | NPC1MEN1KMT2AALDH1A1KCNH2 | |
| SCHEMBL1337347 | 0.87 | KCNH2 (0.43) | KMT2AALDH1A1KCNH2CACNA1BSMN1; SMN2 | |
| SCHEMBL16498153 | 0.87 | KCNH2 (0.43) | KMT2AALDH1A1KCNH2CACNA1BSMN1; SMN2 | |
| SCHEMBL67534 | 0.83 | KMT2A (0.48) | NPC1MEN1KMT2ACACNA1BLMNA | |
| SCHEMBL1334977 | 0.79 | CACNA1B (0.51) | ALDH1A1KCNH2CACNA1B | |
| SCHEMBL16497791 | 0.79 | CACNA1B (0.51) | ALDH1A1KCNH2CACNA1B | |
| SCHEMBL16497805 | 0.79 | CACNA1B (0.51) | ALDH1A1KCNH2CACNA1B | |
| SCHEMBL1336728 | 0.79 | CACNA1B (0.41) | KMT2AKCNH2CACNA1BL3MBTL1 | |
| SCHEMBL1336730 | 0.79 | CACNA1B (0.41) | KMT2AKCNH2CACNA1BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | NPC1 750/4885MEN1 1286/4885KMT2A 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.